Polyethylene glycol compositions for control of relapses of labial herpes, genital herpes and herpes zoster

FIELD: pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, namely to method for reducing the frequency of relapses of labial herpes in patient, which comprises topical administration of therapeutically effective amount of polyethylene glycol (PEG) as an active agent, which is either (i) PEG with average molecular weight of 200–800, or (ii) mixture of (a) PEG with average molecular weight of 200–800 and (b) PEG with average molecular weight of 1000–15000, wherein the weight ratio (a) to (b) ranges from 3:1 to 20:1, wherein said method is performed for at least 4 weeks; topical administration is carried out 1–5 times a day on the lips and/or around the lips of the patient.

EFFECT: invention provides reduction or prevention of relapses of labial herpes.

53 cl, 1 ex, 9 tbl, 1 dwg

 



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry and represents medication, possessing virucidal activity, for preventive and therapeutic treatment of viral infections, caused by virus of herpesviridae family, characterised by the fact that said medication contains pyroxican in carrier substance.

EFFECT: invention provides extension of arsenal of means, possessing virucidal activity.

7 cl

FIELD: medicine.

SUBSTANCE: treating an active form of Epstein-Barr viral infection in the children with an inactive HIV infection involves conducting high-active antiretroviral therapy accompanying administering inosin pranobex prescribed orally from the first day of treatment in a daily dose of 50 mg/kg of body weight, 3-4 times a day to make three courses of 10 days each, as well as using suppositories of interferon alpha-2b + taurine per rectum according to the schedule: for the first 10 days of treatment - one suppository two times a day - in the morning and in the evening, every 12 hours; further - one suppository at the bedtime every second day for three months. The method enables reducing a rate and an intensity of the Epstein-Barr viral infection symptoms by reducing the lymphocyte, blood plasma, oropharyngeal mucus Epstein-Barr virus content and improving the immunological status presented by normalising CD3+ lymphocyte, CD4+ lymphocyte, CD95+ lymphocyte, annexin-V+ lymphocyte, annexin-V+/propidium+ lymphocyte, CD19+ lymphocyte counts.

EFFECT: reducing the rate and intensity of symptoms.

2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: pharmaceutical composition contains a viral preparation containing types 1 and 2 herpes simplex viruses inactivated by formalin or gamma radiation, and an immunocompetent substance. The immunocompetent substance is presented by interferon and a combination of at least two independent amino acids in the following proportions: inactivated types 1 and 2 herpes simplex viruses - 5 mln of plaque-forming units per 1 ml of the suspension, interferon - 150-250 thousand International units/ml, amino acids - 0.27 mg/ml.

EFFECT: adding interferon to the composition as an adjuvant, and also a combination of two irreplaceable amino acids enables creating the high-effective herpes vaccine, preparing a based dosage form in the form of suppositories that makes the vaccine applicable in paediatric practice.

4 cl, 3 ex

FIELD: medicine.

SUBSTANCE: invention provides a stable composition for treating damages associated with herpes-virus infections in a form specified in creams and gels containing low-level trichloroacetic acid. The amount of trichloroacetic acid makes less than 6% (wt / wt) of the cream or gel.

EFFECT: extending the range of products for treating the damages associated with herpes-virus infections.

25 cl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents using sulphated hyaluronic acid for preparing a therapeutic agent for local administration for treating inflammatory/irritating skin diseases specified in dermatitis, atopic dermatitis, photocontact dermatitis, rash, vitiligo, eczema, psoriasis, all skin irritations related to activation of anti-inflammatory cytokines, such as IL-1, IL-2, IL-7, IL-8, IL-9 and TNF, wherein hyaluronic acid has a molecular weight falling within the ranges of 10000 D to 50000 D, 150000 D to 250000 D and 500000 D to 750000 D, and a sulphatation degree equal to 1.

EFFECT: invention provides stimulating the immune system protein synthesis for eliciting the immune response.

8 cl, 33 ex, 15 dwg, 3 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to A-seco-triterpenoids of general formula (I) , where or , demonstrating inhibiting activity with respect to type I herpes simplex virus (HSV-1, strain 1C) and HIV-1. In addition, compounds (I) can be used as intermediates for other biologically active compounds.

EFFECT: increased efficiency of compound application.

2 cl, 1 tbl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the pharmaceutical industry and represents a composition for the external treatment and prevention of infections caused by the type 1, 2 herpes virus and bacterial complications caused by the herpetic infection, containing lysozyme, peroxidase, povyargol as active ingredients, escin and glycyrrhizinic acid or its salts as anti-inflammatory ingredients, liposomes on the basis of high-active hydrated lecithin in a combination with cholesterol as carriers and pharmaceutically acceptable carriers and excipients, with the ingredients of the composition being taken in certain proportions, wt %.

EFFECT: invention provides extending the range of products for treating and preventing the infections caused by type 1, 2 herpes virus and bacterial complications caused by the herpetic infection.

4 ex, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, namely to using a polycarboxylic fullerene C60 derivative as a microbiocidal antiviral agent for the herpes simplex virus (HSV) and cytomegalovirus (CMV) inhibition. The polycarboxylic fullerene C60 derivative has the structural formula .

EFFECT: invention provides the agent for the emergency prevention of HSV and CMV sexual transmission.

7 dwg, 2 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: invention refers to a method of treating recurrent skin and mucosal diseases caused by herpes simplex viruses type 1 and type 2 by coating a damaged region with a preparation containing a base including an active substance - (2,6-dichlorophenyl)amide carbopentoxysulphanic acid of the general formula: wherein X is Na, K, NH4, 2 times a day for 3-5 days, and if observing precursory symptoms, a repeated course of coating with the preparation is performed 1-2 times a day for 2-3 days.

EFFECT: invention provides higher clinical effectiveness in recurrent skin and mucosal diseases caused by herpes simplex viruses type one and type two.

2 cl, 4 ex

FIELD: medicine.

SUBSTANCE: invention represents a drug preparation for treating diseases caused by type 1 herpes simplex and cytomegalovirus, containing recombinant human interferon 2α, lisocyme, Licopid, carnitine 20%, vitamin E and a fatty base.

EFFECT: higher clinical effectiveness and reduced length of treatment, prolonged intercurrent periods, lower recurrent rate by prophylactic administration, reduced manifestation of neurotoxic effects of herpes viruses, lower administration of antibiotics for preventing bacterial complications in infectious-inflammatory diseases caused by herpes simplex virus and cytomegalovirus in children.

2 cl, 3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of invention refers to medicine, namely to oncology, and can be used in treating cancer in a patient. The method involves administering at least one encapsulated chemotherapeutic agent, and at least one amphiphilic block copolymer in this patient. What is also presented is a composition, a kit for treating cancer in the patient and using the amphiphilic block copolymer.

EFFECT: group of inventions provides potentiating the encapsulated chemotherapeutic agent by stimulating the active chemotherapeutic agent release from liposomes by the use of the amphiphilic block copolymer, which is poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) triblock copolymer, in the composition.

10 cl, 11 dwg, 3 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry, and represents a composition containing polyethylene glycol 30 to 150 g, an ascorbic acid ingredient 3 to 20 g specified in ascorbic acid, ascorbic acid salt, or a mixture thereof, alkali or alkali earth sulphate, and at least one electrolyte specified in sodium chloride, potassium chloride, and sodium hydrocarbonate in one litre of an aqueous solution; it additionally contains flavouring agents and is effective in the colon cleansing for preparing for an endoscopy, particularly a colonoscopy. The invention contains a unit dose for preparing the colon cleansing solution, the colon cleansing solution, the method for preparing and using the same, and the kit for preparing and using the colon cleansing solution.

EFFECT: composition is safer than the standard colon cleansing compositions of sodium phosphate, and thereby may be used for the patients exposed to an elevated risk of using the composition of sodium phosphate, and is more tolerable than the standard compositions of PEG (polyethylene glycol) leading to a better compliance with the regimen and providing the effective use by outpatients.

48 cl, 6 ex, 29 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to methods for patient's preparation for diagnostic and therapeutic medical interventions requiring a clean intestine. To prepare the intestine for the medical interventions with using Fortrans (Macrogol), a required quantity of sachets per one intake is calculated according to the table, particularly if a body weight is less than 50 kg and the age is under 50 years old - 1 sachet, the age is between 51 to 70 years old - 1-2 sachets, over 71 years old - 1 sachet, a body weight of 51-70 kg and the age under 50 years old - 1-2 sachets, the age of 51-70 years old - 2-3 sachets, over 71 years old - 2 sachets; a body weight more than 71 kg and the age under 50 years old - 2 sachets, 51-70 years old - 3 sachets, over 71 years old - 2 sachets. Besides, the presence of constipations requires +1 sachet; 1 sachet of Fortrans is dissolved in 1 litre of water.

EFFECT: using the method enables extending the indications, taking into account and coping the contraindications, reducing and eliminating the side effects, preparing in the more sparing regimen with underlying minimal emotional load.

3 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to a method for increasing the efficacy of laevomycetin. This method consists in the fact that laevomycetin in the amount of 1 g in 8.0 ml of distilled water is detoxified and polymerised at first with 1.0 ml of 1% (0.15+0.05%) glutaric aldehyde at 38-40°C for 3-5 days, then added with 1.0 ml of 1% aethonium or 0.1% alkyldimethylbenzylammonium or 0.1% Biopag-D (polyhexamethylene hydrochloride) at 38-40°C for 3-5 days.

EFFECT: method promotes the bactericidal efficacy 3-4 times higher and provides virusocidal and fungicidal action.

4 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to endoscopic surgery and can be used for treatment of early stomach cancer. Fibrogastroscopic visualisation of pathological focus, introduction of endoscopic needle, protrusioning of affected section by injection of solution of liquid, which plays the role of separating film between healthy and pathological tissue of stomach mucosa, are carried out. As protrusioning liquid used is alcohol solution of Bakelite phenolic resin [-C6H3(OH)-CH2-]n. After that, mucosectomy on the zone of hardened film is performed.

EFFECT: method prevents development of bleeding and perforation at the moment of endoscopic mucosectomy, ensures reliable ablation of epithelial stomach tumours of large size in a single block, creates conditions for better healing of post-operative ulcer defect.

4 dwg

FIELD: medicine.

SUBSTANCE: invention refers to compounds of hyperbranched polymer Boltorn H complexes which may be used as substances, bases, ingredients and other biologically active substances in preparing chemopreparations for treating and preventing human fungoid diseases, particularly Candida mycosis, as well as to a method for preparing said compounds. The compounds of hyperbranched polymer Boltorn H complexes contains 10 to 14 groups of propionic or acrylic acids and 10 to 14 metal ions. The given compounds possess anti-candida activity on Candida albicans, Candida krusei, Candida tropicalis, Candida parapsilosis and provides action on the Candida proteinase system and the cell wall components. The method for preparing said compounds consists in synthesis of the compounds containing 10 to 14 groups of propionic or acrylic acids and 10 to 14 metal ions with the use of consecutive reactions of etherification, substitution and addition.

EFFECT: higher preventive and clinical effectiveness in the disease.

2 cl, 3 tbl, 5 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely an antiviral agent. An agent for influenza virus comprises an active substance in the form of an alcohol extract of bee moth larvae, an alcohol extract of propolis and an ointment base containing styrene maleic anhydride copolymer, Vaselin, emulsifier T-2, Cremophore RH-40 and Lutrol F-68, and purified water in certain proportions.

EFFECT: ointment shows manifested antiviral action on influenza virus.

3 dwg, 3 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, particularly to ophthalmology, namely: to antibacterial lenses containing metals, as well as to methods for producing them. The method for producing an antibacterial lens containing a metal salt involves the stages: (a) preparation of a hard lens by a salt precursor, as well as (b) preparation of the lens produced at the stage (a) by a disperse additive specified in a group consisting of polyvinylpyrrolidone, polyvinyl alcohol, glycerol and polyethylene oxide, and a metal-containing agent specified in a group consisting of silver tetrafluoroborate, silver sulphate, zinc acetate, zinc sulphate, copper acetate, copper sulphate, silver nitrate, manganese sulphide, zinc oxide, zinc sulphide, copper sulphide, copper phosphate, silver nitrate, silver sulphate, silver iodate, silver carbonate, silver phosphate, silver sulphide, silver chloride, silver chloride, silver bromide, silver iodide and silver oxide. The other method for producing involves the stages (a) of preparation of a hard lens by a metal-containing agent, and a disperse agent, (b) preparation of the lens prepared at the stage (a) by a salt precursor. The antibacterial lens containing the metal salt is produced by said methods.

EFFECT: group of inventions provides producing the lenses with a decreased degree of opacity.

16 cl, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and pharmacology and represents the use of water-soluble hybrid macromolecular compounds: O-(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionyl)-(1→6)-α-D-glucan, polyethylene glycol bis-3-(3,5-di-tert-butyl-4-hydroxyphenyl)-propionate as agents improving survival rate in wound shock.

EFFECT: invention provides the extended range of products applied in therapy for wound shock.

4 ex, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is presented is using water-soluble hybrid macromolecular compounds O-(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionyl-(1→6)-α-D-glucan and polyethylene glycol bis-3-(3,5-di-tert-butyl-4-hydroxyphenyl)-propionate as erythroprotective agents for phenylhydrazine poisoning. It is shown that the course intravenous introduction of the compounds has manifested erythroprotective action.

EFFECT: invention extends the range of agents applicable in integrated therapy of phenylhydrazine poisoning.

1 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, namely represents composition, which contains mixture of particles of hydrophobic silicon dioxide aerogel, which have specific area of surface per weight unit (Sw) in range from 500 to 1500 m2/g and size, expressed in form of volume mean diameter (D[0.5]), in range from 1 to 1500 mcm, and at least one first linear silicone oil, which has viscosity higher than 50 mm2/s, and at least second and third linear silicone oils, and each of them has viscosity lower than or equal 50 mm2/s.

EFFECT: mixture of particles of silicon dioxide aerogel and linear oils provides possibility of obtaining compositions, which provide comfort and smoothness of skin after application and have dullness and "soft focus"-adding properties.

23 cl, 8 ex

Up!